Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. by Harper, M. E. et al.
Britsh Journal of Cancer (1996) 74, 910-916
©) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Vascular endothelial growth factor (VEGF) expression in prostatic tumours
and its relationship to neuroendocrine cells
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Summary Vascular endothelial growth factor (VEGF) expression was examined by immunohistochemistry in
45 prostatic carcinoma specimens and ten benign prostatic tumours (BPH). The majority of carcinoma
specimens exhibited cytoplasmic staining for VEGF and showed a trend of increasing expression with
dedifferentiation (2p=0.003). Immunoreactive VEGF was also seen in the prostatic carcinoma cell lines, the
order of staining intensity was PC3>DU145>LNCaP. Intense granular cytoplasmic staining for VEGF was
observed in neuroendocrine-like cells which were seen focally in many of the prostatic specimens. Consecutive
sections were incubated with a chromogranin A antibody to confirm the neuroendocrine phenotype of these
cells. A significant correlation (P<0.0001) between the total number of intensely stained VEGF-positive cells
and chromogranin A-positive cells was found. A subpopulation of neuroendocrine-like cells also showed
intense immunoreactivity for transforming growth factor alpha (TGF-a). A correlation was observed
(2p =0.0092) between the intensity of VEGF and TGF-a immunostaining in carcinoma cells which were not of
neuroendocrine differentiation. The presence of these two angiogenic factors may aid the neovascularisation of
carcinomas and their increased expression in tumour-associated neuroendocrine cells may contribute to a more
aggressive phenotype.
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Angiogenesis, the sprouting of new capillaries, in the vicinity
of the tumour cells is a prerequisite of solid tumour growth
(Folkman, 1987). A multitude of factors have been shown to
influence the proliferation, migration and differentiation of
endothelial cells in this process (Folkman, 1990; Zagzag
1995). Measurement of microvessel density (MVD) by
immunolocalisation of factor VIII antigen has been used to
determine the angiogenic activity of a variety of tumours
including breast (Bosari et al., 1992), lung (Yamazaki et al.,
1994) and prostatic cancer (Weidner et al., 1993) and been
found to have prognostic value. Compounds that inhibit the
angiogenic process have shown promise in animal model
systems, reducing solid tumour growth in athymic nude mice
and in rat prostatic cancer (Kim et al., 1993; Vukanonic et
al., 1995).
Vascular endothelial growth factor (VEGF) is a highly
specific mitogen for endothelial cells and a potent micro-
vascular permeability factor (Plate et al., 1994; Neufeld et al.,
1994) and as such may play an integral role in angiogenesis
and thus in the potentiation of solid tumour growth. Indeed,
evidence from studies on brain tumours (Weindel et al.,
1994), renal cell carcinoma (Takahashi et al., 1994), breast
(Brown et al., 1995) and bladder cancer (O'Brien et al., 1995)
indicates that VEGF is often up-regulated when compared
with the normal tissue counterpart.
In prostatic cancer, measurement of MVD has been found
to be prognostic (Hall et al., 1994), whether a relationship
exists between MVD and the expression of VEGF and/or
basic fibroblast growth factor (FGF) in malignant disease of
this gland may have implications for therapy. In this respect
assays on breast tumours (Toi et al., 1994) and epidermoid
lung carcinomas (Mattern et al., 1996) have demonstrated a
correlation between VEGF expression and MVD measure-
ments. Recent studies have indicated that measurement of
intratumoral levels of VEGF may be useful in assessing the
activity of tumour angiogenesis (Toi et al., 1996). In a study
on renal cell carcinomas, VEGF was up-regulated, but not
basic FGF (Takahashi et al., 1994). To date, VEGF has not
been identified in prostate tissue so it was considered
important to determine if this growth factor is involved in
neoplastic changes in this organ. A series of prostatic
carcinomas, benign tumours and prostatic cell lines were
therefore examined for the presence of VEGF.
In the course of this study it became apparent that a
subpopulation of cells with neuroendocrine characteristics
were expressing immunoreactive VEGF in large amounts.
Neuroendocrine cells, which are known to secrete a variety of
peptides and biogenic amines (Di Sant'Agnese, 1992), have
been found in 50% of prostate cancers (Di Sant'Agnese and
de Mesey Jensen, 1987) and their presence indicates a poor
prognosis in this malignancy (Cohen et al., 1991). In view of
these findings, immunohistochemical assays were undertaken
on consecutive sections of the prostatic tissue to determine
the neuroendocrine cell distribution and to establish the co-
expression of VEGF and chromogranin A in this particular
cell type.
Another growth factor which appears to have potential as
a prognostic marker in malignant disease (Bebok et al., 1994;
Sauter et al., 1995; Reinartz et al., 1994) and indeed has been
demonstrated in increasing amounts with dedifferentiation in
prostatic adenocarcinoma (Harper et al., 1993), is transform-
ing growth factor a (TGF-cx). Its presence has been noted in
prostate cancer cells with neuroendocrine morphology
(unpublished data) and in the light of these observations,
coupled with the reported angiogenic properties of TGF-a
(Yamamoto et al., 1994; Ono et al., 1992), expression of this
factor was examined in relation to chromogranin A and
VEGF distribution. The role that neuroendocrine cells may
play in tumour progression is probably multifold (Aprikian et
al., 1993), one important aspect of which might involve
secretion of angiogenic substances, such as VEGF and TGF-
ax, aiding capillary growth and vascular permeability.
Materials and methods
Prostatic tissue
Prostate tissue was obtained from 45 patients with
histologically diagnosed prostatic carcinoma and ten patients
with benign prostatic hyperplasia (BPH). Forty-four of the
patients with carcinoma and nine of the patients with BPH
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1996underwent transurethral resection (TURP) of their tumours,
while the remaining two patients had open prostatectomy
operations. A representative sample of the curettings from
the operations was fixed in formal saline followed by paraffin
wax embedding for subsequent histopathological examination
and the VEGF, chromogranin A and TGF-c immunohisto-
chemical assays. Grading of the tissues was carried out using
the WHO classification (Mostofi et al., 1980).
Prostatic carcinoma cell lines
The DU145, LNCaP and PC3 cell lines were cultured as
described previously (Glynne-Jones et al., 1994). For use in
immunocytochemical analysis the cells were seeded onto
sterile TESPA (3-aminopropyl-triethoxy-silane; Sigma Che-
mical Co., Dorset, UK) coated coverslips in tissue culture
dishes. After 72 h in culture (i.e. still in logarithmic growth)
the monolayers were washed in unsupplemented medium and
fixed in formal saline (10 min at room temperature),
transferred to 70% ethanol (2 x 5 min) and then to
phosphate-buffered saline (PBS).
Immunocytochemical analysis
Immunocytochemical analysis was performed on 5,m
consecutive sections of the formal saline-fixed wax-embedded
tissues and the cell line monolayers. Sections were dewaxed
and taken through graded alcohols to PBS (0.01 M, pH 7.4)
followed by incubation for 5 min with 0.3% hydrogen
peroxide to block endogenous peroxidase for both the
TGF-a and chromogranin A assays. After dewaxing and
rehydration the sections assayed for VEGF immunostaining
were microwaved 2 x 10 min at maximum power in sodium
citrate buffer, pH 6. These sections were washed with PBS,
2 x 5 min, before blocking endogenous peroxidase with
hydrogen peroxide.
Blocking of endogenous peroxidase in the coverslip
cultures was carried out by incubation with 50 jiM
phenylhydrazine in PBS for 10 min at 37°C followed by
20 min incubation at 37°C with 0.005% hydrogen peroxide in
50 gM phenylhydrazine in PBS. The coverslips were then
washed, 2 x PBS, before incubation with the VEGF antibody.
VEGF assay Immunostaining for VEGF used a rabbit
polyclonal antibody (Santa Cruz Biotechnology, supplied by
Autogen Bioclear UK, Devizes, Wiltshire, UK). The primary
antibody (1 ,ug ml-') was incubated for 1 h at room
temperature. After washing the antigen was detected using
the streptavidin -biotin Universal kit system (Diagnostic
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protocol and immunolocation of VEGF was visualised with
the chromogen 3-amino-9 ethyl carbazole. Sections were
lightly counterstained with 10% haematoxylin and mounted
in Aquamount (BDH Chemical Co., Poole, UK).
Semiquantitative analysis of cytoplasmic VEGF staining
was carried out by two independent observers. Each section
was scanned in its entirety and a score was assigned
according to the intensity of the immunoreaction in the
prostatic epithelial or carcinoma cells (excluding those of
neuroendocrine differentiation) (0, no staining; +/-, very
low; 1 +, low; 2+, moderate; 3+, strong). Neuroendocrine-
like cells were intensely stained, equivalent to 4+ to 5 + on
the above scale of intensity. The total number of these cells
were counted.
Chromogranin A assay Sections were washed in PBS before
incubation for 1 h with a monoclonal antibody to chromo-
granin A (Novacastra Laboratories, Newcastle-upon-Tyne,
UK) at a dilution of 1/50. Antigen binding was detected
using the streptavidin-biotin Universal kit (Diagnostic
Products) as per protocol with the chromogen 3-amino-9-
ethyl carbazole. Sections of human pituitary and adrenal
were included in these assays as positive control tissues for
the presence of chromogranin in neuroendocrine cells.
A semiquantitative score of 0, +/-, 1+, 2 + or 3 + was
assigned according to the relative abundance of positive cells.
In addition the total number of positive cells was counted per
section.
TGF-a assay Assay procedures using a monoclonal human
TGF-a antibody (Oncogene Science, distributed by Cam-
bridge Bioscience, Cambridge, UK) and the indirect
peroxidase-conjugated streptavidin-biotin detection method
have been described previously (Harper et al., 1993). The
intensity of staining was scored as 0, +/-, 1+, 2 + or 3+.
In addition the total number of neuroendocrine cells per
section identified by their intense TGF-a immunoreaction,
was counted.
Absorption studies To test the specificity of the VEGF
immunostaining observed, the antibody was incubated over-
night with various compounds: VEGF peptide, a 20 amino
acid synthetic peptide corresponding to residues 1 to 20 of the
amino terminus of VEGF (Santa Cruz) at 10 ig ml-1 final
concentration; PDGF-AB human recombinant (Sigma Che-
mical Co.) at a final concentration 5 jg ml-1; TGF-c, human
recombinant (R&D Systems Europe, Abingdon, UK) at
10 jg ml-' final concentration; bovine serum albumin (BSA)
(Sigma Chemical Co) at 10% final concentration. Consecutive












Figure 1 Histographical analysis of cytoplasmic staining for VEGF and TGF-ac in benign glandular epithelium or carcinoma cells
which are not ofneuroendocrine differentiation. The percentage of specimens at the various intensity scores is plotted from 0 to 3 +.
A trend towards increasing expression with dedifferentiation can be seen in carcinoma specimens.
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differentiation, a BPH specimen and the prostatic cell lines
cultured on coverslips were incubated with the various
absorbed and unabsorbed antibody solutions at 1 ig ml-'
final concentration and assay by the standard procedure. The
VEGF peptide was able to completely absorb the staining seen
with the VEGF antibody on the sections. None of the other
peptides or proteins diminished the staining on any of the
specimens. Furthermore, the staining seen with the TGF-a and
chromogranin A antibodies was not altered by prior
absorption with the VEGF peptide.
Figure 2 Immunohistochemical distribution of VEGF (a,c), chromogranin A (b,d) and TGF-a (e,f) in prostate carcinoma cells of
neuroendocrine differentiation. Sections have been lightly counterstained with haematoxylin to clarify the morphology
(magnification x450). a and b are consecutive sections of a well-differentiated carcinoma and c and d adjacent sections of a
cribriform tumour, demonstrating the co-localisation of VEGF (a and c) and chromogranin A (b and d) in neuroendocrine cells. In
e and f intense cytoplasmic staining for TGF-a is seen in neuroendocrine-like cells in a poorly differentiated (e) and a moderately
differentiated (f) prostate carcinoma.Statistics
Spearman's rank correlation was used to analyse the data
obtained. Linear regression plots of the number of
neuroendocrine cells detected by chromogranin A, VEGF
and TGF-a immunodetection were performed.
Results
Clinical samples
VEGF immunoassays Diffuse cytoplasmic staining of 0 to
1 + intensity was observed in BPH secretory epithelium with
intense staining of occasional neuroendocrine-like cells within
the glandular structures. Neuroendocrine cells present in the
TSH- and FSH-secreting cells ofthe anterior human pituitary
and the chromaffin cells of the adrenal medulla also exhibited
intense VEGF staining.
The majority of carcinoma specimens exhibited cytoplas-
mic staining for this growth factor which showed a trend of
increasing VEGF expression with dedifferentiation (Figure 1)
(2p =0.003). This result was similar to that seen for TGF-oa
cytoplasmic staining in the consecutive sections (Figure 1)
(2p=0.0349). In the carcinoma specimens a correlation was
found between the expression of these two growth factors
(2p=0.0092). Intense (3+) cytoplasmic granular immunolo-
calisation of VEGF in a neuroendocrine-like cell population
was also demonstrated in carcinomas (Figure 2 a and c).
These cells were often seen focally in the moderately
differentiated carcinomas particularly in cribriform tumours.
These strongly stained VEGF cells were observed in 25/45
carcinomas (55%) and 18/22 (81%) BPH specimens.
Another cell type that was intensely stained with the
VEGF antibody was that of polymorphonuclear neutrophils
as seen in the blood vessels and in the stroma, particularly
noticeable in those attached to vessel walls in areas of
inflammation or infection in the BPH specimens.
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A heterogeneous distribution of neuroendocrine cells was
detected in the adenocarcinomas with a range of positivity
(Figure 3). Up to 5% of the tumour cells were chromogranin
A-positive in areas of focal neuroendocrine differentiation.
Occasionally isolated positive cells were seen in the stroma of
infiltrative carcinomas. The incidence of chromogranin A-
positive cells was greatest in grade 2 tumours (Figure 3) and
it was noticeable that the majority were associated with a
cribriform morphology (Figure 2d). There was also evidence,
within cribriform areas of the tumour, of disintegration of
individual neuroendocrine cells, their contents immunologi-
cally detectable in the intraluminal spaces. In benign tissue
chromogranin A-positive cells were localised within the
glandular epithelium. Generally only a few scattered positive
cells were seen with focal immunoreactivity in dysplastic
acini, often associated with infection.
Regression analysis of the number of neuroendocrine cells
identified by the chromogranin A and VEGF assays in both
adenocarcinomas and BPH specimens showed a close
correlation (P<0.0001) (Figure 4). Similar distributions of
VEGF and chromogranin A-positive cells could be seen in
the individual tumours (Figure 2a-d) indicating co-expres-
sion in some cells.
U-
LU
Chromogranin A assays Neuroendocrine cells defined by
their reactivity with chromogranin A were identified in 25 of
the 45 carcinoma specimens (55%) and 19 of the 22 BPH
specimens (86%). Included in the latter group are 12




























Figure 3 Relative abundance ofchromogranin A-positive cells in
BPH and carcinoma specimens showing the degree of neuroendo-
crine differentiation. A semiquantitative score from 0 to 3 + was
assigned and the percentage of specimens at each score is plotted
for BPH and the three grades of cancer (Mostofi et al., 1980).
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Figure 4 Regression analysis of the total number of neuroendo-
crine cells within a section, as defined by chromogranin positivity,
vs total neuroendocrine cells immunoreactive for VEGF
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TGF-a immunocytochemical assays A subpopulation of the
neuroendocrine-like cells was intensely stained with the TGF-
a antibody (Figure 2 e and f) and a correlation was found
between the number of these cells and the total population of
neuroendocrine cells as identified by chromogranin A
localisation (Figure 4). Some neuroendocrine-like cells, as
judged morphologically, stained intensely for TGF-a but
were not chromogranin A-positive and vice versa. The
remainder of the neuroendocrine cells showed a similar level
of TGF-a immunoreactivity as the secretory epithelium of
BPH glands or the cytoplasm of the carcinoma cells within
the tissue section, as given by the TGF-ax score. There was no
correlation between this TGF-a score and the level of
neuroendocrine differentiation, as defined by the chromo-
granin A score. Cytoplasmic staining for TGF-a was seen in
the majority of carcinomas which related to histological
grade in agreement with previous studies (Harper et al.,
1993).
Cell lines
VEGF expression was observed in the cell lines PC3, DU145
and LNCaP examined. The staining was diffuse, located in
the cytoplasm but not associated with any subcellular
fraction. Absorption experiments indicated that this staining
detected with the antibody was specific for VEGF. The
staining seen was not diminished by incubation of the
antibody with PDGF, TGF-a or BSA. The order of
expression of VEGF as judged by intensity of staining was
PC3 >DU145 > LNCaP.
Discussion
A variety of factors have been found to influence the
proliferation, migration and differentiation of endothelial
cells but one of the more specific mitogens of capillary
endothelium is a member of the platelet-derived growth factor
(PDGF) family, vascular endothelial growth factor/vascular
permeability factor. Although increased expression of this
factor has been detected in several carcinomas when compared
with their normal tissue counterparts (Takahashi et al., 1994;
O'Brien et al., 1995), its presence has not previously been
reported in prostate tumour specimens or prostatic cell lines.
This immunohistochemical study indicates that VEGF is
present in both the benign and malignant prostate specimens,
with the carcinomas having a slightly increased expression as
judged by their cytoplasmic staining intensity. It would
appear that a source of this particular cytokine is present
within the majority of these tumours and may play a role in
the neovascularisation essential for tumour growth and
metastatic spread.
One of the ways in which the angiogenic activity of a
tumour is assessed is by measurement of the microvessel
density (MVD) in the tissue specimen by using antibodies to
blood vessel markers such as factor VIII. Increased MVD has
been correlated with a higher incidence of metastasis and a
worse prognosis in both breast (Weidner et al., 1992; Horak
et al., 1992) and prostatic carcinoma (Vesalainen et al., 1994;
Wakui et al., 1992). Two studies in prostate cancer, one in
invasive carcinoma (Weidner et al., 1993) and the other in
clinically localised disease (Hall et al., 1994), concluded that
MVD had prognostic potential. In non-small-cell lung
carcinoma the MVD measurements also related to progres-
sion (Macchiarini et al., 1992).
There is some evidence that angiogenic activity is more
important at earlier stages of growth when the tumour
changes from an avascular to vascular phase (Vesalainen et
al., 1994). Experiments on tumour transplantation into nude
mice indicate that tumour take and growth are very
dependent on this feature, more so than mitotic rates, and
furthermore, administration of antibodies to VEGF has been
shown to slow xenograft growth (Kondo et al., 1993; Kim et
al., 1993).
It is possible that alternative angiogenic pathways may be
operating in the various tumours. In bladder cancer, VEGF
expression was higher in superficial tumours than invasive
tumours whereas platelet-derived endothelial cell growth
factor expression was higher in the invasive compared with
the superficial bladder tumours (O'Brien et al., 1995). In this
same study VEGF expression in the superficial bladder
cancer patients predicted progression.
Basic fibroblast growth factor (FGF) is also a potent
mitogen of endothelial cells as well as many other cell types
and is expressed in a variety of tumours (Benharroch and
Birnbaum, 1990). In the transplantable human prostatic
carcinoma line, Tenl2, which is extremely angiogenic in nude
mice, VEGF expression was not detected, but its secretion of
basic FGF however was found to be 5-fold higher than that
of the other prostate cell lines, PC3, DU145 and LNCaP
(unpublished work). All three in vitro prostatic cell lines
expressed VEGF as detected immunohistochemically. It is
possible that the prostatic carcinomas which were negative
for VEGF (15%) in this study may express alternative
angiogenic compounds such as basic FGF which aid their
neovascularisation. In a study ofbenign and malignant breast
tumours higher levels of acidic and basic FGF mRNAs were
found in the benign specimens although approximately 25%
of the carcinomas had equally as high concentrations of basic
FGF mRNA (Anandappa et al., 1994). This indicates that
carcinomas, within an organ type, have the ability to express
and possibly use different cytokines for growth and
angiogenesis.
Of interest in this current study was the observation that
the neuroendocrine cells present in the prostatic tumours
exhibited intense staining for VEGF. A correlation was found
between the total number of chromogranin A-positive cells
and the total number of VEGF-containing neuroendocrine-
like cells in individual tumours. Furthermore, consecutive
sections indicated that these were almost certainly the same
cells (see Figure 2 a-d). These VEGF-positive neuroendo-
crine cells were more frequently observed in cribriform
tumours which is reminiscent of the distribution of paneth-
like cells described in prostate tumours (Adlakha and
Bostwick, 1994).
Neuroendocrine cells were found in 55% of the carcinoma
specimens in this current study which is a similar incidence to
that reported by other groups (Cohen et al., 1990). They
express prostate-specific antigen (PSA) (Aprikian et al., 1993;
Cohen et al., 1992) and are believed to represent a third
epithelial type originating from a common stem cell. As these
cells do not appear to proliferate (Bonkhoff et al., 1991), it is
assumed that the increased numbers seen in the tumours
originate from prostatic carcinoma cells which are induced to
undergo neuroendocrine differentiation. Prostatic neuroendo-
crine cells lack androgen receptor and it has been suggested
that they could represent an androgen-insensitive cell
population that can expand in some cases to populate the
tumour (Krijnen et al., 1993). There does, however, appear to
be three types of prostatic tumours with neuroendocrine
differentiation (Di Sant'Agnese, 1992) and the most common
pattern, adenocarcinoma with focal neuroendocrine differ-
entiation, is the one seen in this study. Small-cell carcinoma
of the prostate is, however, prostate-specific antigen (PSA)
and androgen receptor negative and, as elsewhere, is a highly
expansive and aggressive tumour.
The majority of the prostatic neuroendocrine cells secrete
serotonin and to lesser extents TSH, calcitonin and gastrin-
releasing peptide (Abrahamsson et al., 1987). Many of these
peptides are thought to influence progression of the tumours
via their growth-regulatory activities. More importantly the
number of neuroendocrine cells in prostatic cancer correlated
with poor prognosis (Cohen et al., 1991; Turbat-Herrera et
al., 1988). The presence of a whole variety of neuropeptides
and cytokines in these cells, which could act in a paracrine
manner on the neighbouring cancer cell population, probably
accounts for their relationship to tumour aggressiveness and
progression. Increased expression of VEGF in neuroendo-VEGF i prostatic bnows
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cnne cells could also influence progression via its local
angiogenic activity and. because of its action on vascular
permeability, might facilitate metastatic spread. Expression of
the angiogenic factors PDGF and basic FGF has been
demonstrated in neuroendocnrne tumours of the digestive
system (Chaudhry et al.. 1993) and marked vascular
proliferation observed in brain metastases of small-cell lung
carcinomas which related to basic FGF expression (Ito et al..
1993) but no evaluation of VEGF expression was made in
either study.
The observation that TGF-2 is expressed in a subset of the
neuroendocrine cells would suggest that this factor may
contribute to the unfavourable prognosis of the particular
patient. TGF-z, in addition to having angiogenic properties
(Schreiber et al.. 1986). has prognostic relevance (Bebok et
al.. 1994: Sauter et al.. 1995) and is also capable of
stimulating prostatic cell growth in an autocrine and or
paracrine manner via the EGFR receptors which are present
in many of the prostate adenocarcinomas (Harper et al..
1995). Recently TGF-x has been reported to be expressed in
all 30 neuroendocrine tumours examined, which included
carcinoid tumours of the midgut. medullary thyroid
carcinomas and phaeochromocytomas (Nilsson et al., 1995).
Large amounts of TGF-x were also found to be secreted into
the medium by primary cultures of carcinoid tumours and
phaeochromocytomas (Nilsson et al., 1995). Several other
growth factors. IGF-1 IGF-I1 PDGF and TGF-fi, have also
been detected in carcinoid tumours (Beauchamp et al.. 1991:
Chaudhry et al.. 1992: Nilsson et al.. 1992). There are reports
that the cell lines PC3 and LNCaP display certain
neuroendocrine characteristics expressing markers of the
neural crest in addition to epithelial markers. In response
to cyclic AMP analogues they were shown to differentiate
terminally, with epithelial cell markers being down-regulated
whereas neurone-specific enolase was elevated (Bang et al..
1994). Furthermore. all three prostate cell lines have been
shown to be growth inhibited by selective serotonin receptor
antagonists such as pindobind (Abdul et al.. 1994). PC3.
DU145 and LNCaP cell lines are known to express TGF-.7
(Schurmans et al.. 1991: Ching et al.. 1993: Liu et al.. 1993)
and in the latter line the response is modulated by androgens.
It was noticed that some TGF-a-containing neuroendo-
crine-like cells were negative for chromogranin A and may
represent a cell subpopulation which is chromogranin B
positive. In some poorly differentiated prostatic tumours
chromogranin B is the major component (Schmid et al..
1994).
Polymorphonuclear leucocytes were also strongly stained
with VEGF antibody which appeared specific according to
the absorption studies. They were noticeable in vessels
adjacent to infection and or inflammation. It is possible
that the vascular permeability function of this factor may be
more relevant in this situation.
In conclusion, this study indicates that the majority of
prostatic tumours express VEGF which may aid their
neovascularisation. The neuroendocrine cells present focally
in many of the tumours appear to express VEGF in large
amounts and a subpopulation of these secrete TGF-x. In
addition to their production of a variety ofcompounds which
can act in a paracrine manner to stimulate adjacent cancer
cell growth, the storage of these two angiogenic factors in
such cells provides another pathway by which neuroendo-
crine cells could influence the progression of this disease.
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